Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 75.12M P/E - EPS this Y -10.00% Ern Qtrly Grth -
Income -21.26M Forward P/E -2.62 EPS next Y - 50D Avg Chg -9.00%
Sales 2.16M PEG - EPS past 5Y - 200D Avg Chg -34.00%
Dividend N/A Price/Book 2.27 EPS next 5Y - 52W High Chg -63.00%
Recommedations 1.50 Quick Ratio 5.64 Shares Outstanding 217.26M 52W Low Chg 6.00%
Insider Own 2.92% ROA -37.76% Shares Float 210.48M Beta 1.53
Inst Own 12.05% ROE -68.84% Shares Shorted/Prior 1.47M/1.42M Price 0.34
Gross Margin - Profit Margin - Avg. Volume 485,632 Target Price 0.65
Oper. Margin -1,081.94% Earnings Date Mar 27 Volume 181,336 Change -3.13%
About Matinas Biopharma Holdings, Inc

Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is LYPDISO, a prescription-only omega-3 fatty acid-based composition intended for the treatment of cardiovascular and metabolic conditions. The company also offers MAT2203, an oral formulation of amphotericin B that is in Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients. In addition, it provides MAT2501, an orally administered formulation of the broad-spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various types of multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as various multidrug-resistant gram negative and intracellular bacterial infections. Matinas BioPharma Holdings, Inc. has a research collaboration with the National Institute of Allergy and Infectious Diseases for the development of Gilead's antiviral remdesivir; and a feasibility collaboration with Genentech, Inc. for the development of oral formulations. Matinas BioPharma Holdings, Inc. was incorporated in 2013 and is based in Bedminster, New Jersey.

Matinas Biopharma Holdings, Inc News
03/27/24 Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update
03/25/24 Matinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel Formulation
03/22/24 Why Is Fungal Infections-Focused Matinas BioPharma Stock Trading Higher On Friday?
03/22/24 Three Patients with Invasive Fusarium Infection in Matinas BioPharma’s Oral MAT2203 Compassionate/Expanded Use Access Program Achieve Complete Clinical Response
03/22/24 Matinas BioPharma Regains Compliance with NYSE American Continued Listing Standards
02/26/24 Matinas BioPharma Provides Positive Outcomes Update on the MAT2203 Compassionate/Expanded Use Access Program, Including Multiple Patients with Complete Clinical Resolution
02/20/24 Matinas BioPharma Successfully Reaches Agreement with FDA for a Single Phase 3 Registration Trial to Support an NDA for MAT2203 for the Treatment of Invasive Aspergillosis
01/03/24 Matinas BioPharma to Present at Biotech Showcase 2024
12/27/23 Matinas BioPharma Demonstrates in vivo Biological Activity and Disease Improvement in Two Inflammatory Disease Models with Oral LNC-Delivered Small Oligonucleotides
12/21/23 Matinas BioPharma Provides Update to MAT2203 Regulatory and Development Pathway Following Feedback from FDA
11/10/23 Matinas BioPharma Holdings, Inc. (AMEX:MTNB) Q3 2023 Earnings Call Transcript
11/09/23 12 Best Day Trading Stocks To Buy
11/09/23 Q3 2023 Matinas BioPharma Holdings Inc Earnings Call
11/08/23 Matinas BioPharma Holdings Inc (MTNB) Reports Q3 2023 Financial Results and Business Progress
11/08/23 Matinas BioPharma Reports Third Quarter 2023 Financial Results and Provides a Business Update
11/07/23 Matinas BioPharma Announces Positive in vivo Efficacy Results of Oral LNC Docetaxel Formulation in a Melanoma Model
11/01/23 Matinas BioPharma to Webcast Conference Call to Discuss Third Quarter 2023 Financial Results and Provide a Business Update on November 8, 2023
10/11/23 Patient with Candida krusei Infection in Matinas BioPharma’s Oral MAT2203 Expanded Access Program Achieves Complete Clinical Resolution
06:00 AM Matinas BioPharma to Present at Two Investment Conferences in October 2023
09/27/23 Matinas BioPharma to Feature MAT2203 in a Pipeline Presentation at IDWeek
MTNB Chatroom

User Image DeepValueStocks Posted - 9 minutes ago

$MTNB Near-term TA looking lovely: BREAKOUT TRADE: Watch for possible breakout above 0.299 Target: 0.361, 24.5% Stop: 0.267 Loss: 7.9% P/L ratio: 3.1 : 1 - Excellent

User Image DeepValueStocks Posted - 13 minutes ago

$MTNB If a multi-regional partnership deal for MAT 2203 and our *OTHER.....(*cancer, inflammation, colitis, psoriasis)LNC assets are around the corner (2Q24), shouldn't analysts bump up their existing PTs ??? And if they don't, can we all assume that "silent upgrades" were likely made ?

User Image Navtalk Posted - 1 hour ago

$MTNB if partnership happens and from them if we get funding for trial 3 . Will stock price goes up?

User Image DOC1977 Posted - 1 hour ago

$MTNB overall things r looking better , just need the cash and I’m sure with the positive data we have in different areas I think a partnership is imminent…….

User Image levystrauss Posted - 2 hours ago

$MTNB I don't know what to think, but if the science is as good as it seems, they should make an OFFERING for $1 and see if it works. Maybe they could buy 10 million shares themselves with their own money, producing a boomerang effect on the future price....but this is a financial fantasy...:-))))

User Image tdohm22 Posted - 4 hours ago

$MTNB

User Image BlaznBull Posted - 8 hours ago

$MTNB https://www.google.com/amp/s/forextv.com/top-news/matinas-biopharma-reports-2023-financial-results-and-provides-a-business-update/amp/

User Image valueforme Posted - 10 hours ago

$MTNB If we can dream of a Big Pharma at MAT2203 global anti-infectives partner, what are the options? Top-5 is below. Let's review: - Merck? Nothing in the anti-infectives pipeline for years, do they still care? - Gilead? Challenging history of previous relationships, AmBisome market share (why to buy something to compete with your other product) - GSK? Maybe, they are doing interesting deals recently, e.g. Spero - Pfizer? No, they got rid of another antifungal asset recently. - Novartis? Not Novartis, but Sandoz, their generics spin-off. Maybe, they bought Mycamine rights a year ago. GSK or Sandoz would be f*cking awesome. But big boys are not quick to sign deals with.

User Image tdohm22 Posted - 10 hours ago

$MTNB

User Image bagholderluck Posted - 11 hours ago

$MTNB These mat2203 offers must be amazing for J and team not to accept them. Wait, that makes no sense.

User Image shakeslear86 Posted - 11 hours ago

$MTNB I am impressed with several outcomes. (1) The price in the after market has held up. (2) The team is not looking for BARDA $ but focussed on one or more partners with a strong world wide sales force. Do this in Q2. And they will likely be focussing on LNC/chemo as their second LNC/generic product. Sounds good to me with low risk and huge market. I am hoping a 2203 partner is a candidate for doing LNC/docetaxel also. Setting up LNC manufacturing for 2203 should help set up for other payloads.

User Image febiyanr Posted - 11 hours ago

$MTNB when is the next catalyst? I was expecting something big from the ER haha.

User Image valueforme Posted - 12 hours ago

$MTNB The funny thing is that they never filed Feb 2022 Rutgers Second Amended and Restated Exclusive License Agreement with SEC, so we don't know what is a deadline for Rutgers license to terminate for non commencing commercial sales. Original agreement had 29th of January, 2015 as a restatement date and this termination close: "Nine (9) years have elapsed from the RESTATEMENT DATE, LICENSEE, an AFFILIATE or a sublicensee has not commenced commercial sales of at least one LICENSED PRODUCT, and LICENSOR has given LICENSEE ninety (90) days’ notice of intent to terminate."

User Image tdohm22 Posted - 12 hours ago

$MTNB I think I’ve developed a thyroid condition from these guys….I do not feel well

User Image DeepValueStocks Posted - 12 hours ago

$MTNB In summary, a global licensing deal will happen but it's simply a question of "when". Big pharma pulls the trigger when big pharma decides to pull the trigger. 2203 is ready to go and the LNC factory is busy looking to expand into cancer, inflammation, colitis and psoriasis. What's not to like ?

User Image Mario081 Posted - 12 hours ago

$MTNB The prerequisites are good, but not what we wanted to hear. I'm hoping for a short sell-off due to the failure to deliver the promised results in Q 1 so that we can buy again, and then maybe we'll see each other again at the end of May with new information, until then there will be radio silence again.

User Image RedOneBNTX Posted - 12 hours ago

$MTNB I liked the discussion about the cost savings of MAT2203 for hospitals and insurance, which will increase the price of the pills.

User Image tdohm22 Posted - 13 hours ago

$MTNB 4 more years guys….then we may get back over $1.00! Let the good times role baby. Down payment on a Toyota here I come!!

User Image RoyBaschMD Posted - 13 hours ago

$MTNB be patient and everything will be good at the end 👍🏻

User Image Terps99 Posted - 13 hours ago

$MTNB did they say anything about r/s or offering. Anything like that? Just got out of work

User Image omega42 Posted - 13 hours ago

$MTNB two words to summarize "cautiously optimistic" and currently I want to see a partner irrespective of timeline it take to enroll and get it to market. Secondly, with 65 sites across different continents, it should be rather quick process to enroll patients....less than 4 per each site and why does it need to take 2 years to enroll?

User Image epster Posted - 13 hours ago

$MTNB Telephone music was "set fire to the rain" by Adele. How fitting for the passionate loyal MTNB investors. lol. Gemini: The song is about a passionate and stormy relationship. Lines like "Cause there's a side to you / That I never knew, never knew" and "All the things you'd say / They were never true, never true" depict a love that's falling apart. The rain symbolizes tears and sadness, and "setting fire to the rain" becomes a metaphor for the intensity of the emotions involved.

User Image mdrins00 Posted - 13 hours ago

$MTNB so think about this for a minute...we're FOUR years away from a potential MAT2203 launch. you know both JJ and TM just hated uttering "Twenty.....Twenty Eight". reality check: how long do you think it will take to possibly, maybe, launch an LNC formulation of ANYTHING oncology or inflammation related? if you have toddlers at home, today, they will be in highschool by the time that day comes to pass. and given the rapidly evolving delivery landscape, does LNC have that long?

User Image DeepValueStocks Posted - 13 hours ago

$MTNB Jerry's hesitancy to talk with bravado is a good sign that he learned his lesson from BNTX and is listening to his advisors. Said something earlier that we should hear about more milestones in 2Q24 (Deal announcement ?)

User Image mdrins00 Posted - 13 hours ago

$MTNB 4 yrs until commercial launch. that is the price for all this dicking around.

User Image valueforme Posted - 13 hours ago

$MTNB Potential approval in 2028, what if someone told you that in Sept 2021 when EnAct Cohort 2 data was out?

User Image tdohm22 Posted - 13 hours ago

$MTNB c’mon…ask him the only question that matters…why does the market never validate our science, but does so with every single other biotech company? Especially, with the illiquidity of the pre-market when our news is often delivered and the pedigree of our BOD.

User Image DeepValueStocks Posted - 13 hours ago

$MTNB They are going the partnership route asap to not only monetize 2203 but also their other assets in cancer & inflammation, and they said they are looking for a multi-regional deal.

User Image tdohm22 Posted - 13 hours ago

$MTNB hey BTIG! While we have you here…where is our price target reiteration. I’ll help you out….should be $6.00 per share

User Image markmorrow Posted - 13 hours ago

$MTNB Extended the cash from into the 3rd Q to the end of 3rd q.

Analyst Ratings
HC Wainwright & Co. Buy Jan 31, 23
Aegis Capital Buy Aug 13, 20
Piper Sandler Overweight Jan 27, 20
SunTrust Robinson Humphrey Buy Jan 24, 20
HC Wainwright & Co. Buy Jun 26, 19
BTIG Buy May 17, 19
Roth Capital Buy Feb 11, 19
Maxim Group Buy Nov 13, 18
Maxim Group Buy Aug 13, 18